Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-9193
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Repurposing beta-3 adrenergic receptor agonists for Alzheimer’s disease: beneficial effects in a mouse model ; volume:13 ; number:1 ; day:21 ; month:5 ; year:2021 ; pages:1-17 ; date:12.2021
Alzheimer's research & therapy ; 13, Heft 1 (21.5.2021), 1-17, 12.2021
- Creator
-
Tournissac, Marine
Vu, Tra-My
Vrabic, Nika
Hozer, Clara
Tremblay, Cyntia
Mélançon, Koralie
Planel, Emmanuel
Pifferi, Fabien
Calon, Frédéric
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13195-021-00842-3
- URN
-
urn:nbn:de:101:1-2021091909501815894336
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tournissac, Marine
- Vu, Tra-My
- Vrabic, Nika
- Hozer, Clara
- Tremblay, Cyntia
- Mélançon, Koralie
- Planel, Emmanuel
- Pifferi, Fabien
- Calon, Frédéric
- SpringerLink (Online service)
Other Objects (12)
Single-cell-led drug repurposing for Alzheimer’s disease
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
Muscarinic agonists and the treatment of Alzheimer's disease
Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance
Beneficial effects of curtailing immune susceptibility in an Alzheimer’s disease model
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Altered pharmacological effects of adrenergic agonists during hypothermia
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Single-cell-led drug repurposing for Alzheimer’s disease
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
Muscarinic agonists and the treatment of Alzheimer's disease
Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance
Beneficial effects of curtailing immune susceptibility in an Alzheimer’s disease model
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Altered pharmacological effects of adrenergic agonists during hypothermia
Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
Single-cell-led drug repurposing for Alzheimer’s disease
In silico repurposing of antipsychotic drugs for Alzheimer’s disease
Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer’s disease mice
Repurposing dapagliflozin for Alzheimer's disease: a mechanistic exploration
Reconsidering repurposing: long-term metformin treatment impairs cognition in Alzheimer’s model mice
Artificial intelligence framework identifies candidate targets for drug repurposing in Alzheimer’s disease
Muscarinic agonists and the treatment of Alzheimer's disease
Glaucoma and Alzheimer: Neurodegenerative disorders show an adrenergic dysbalance
Beneficial effects of curtailing immune susceptibility in an Alzheimer’s disease model
High-throughput target trial emulation for Alzheimer’s disease drug repurposing with real-world data
Altered pharmacological effects of adrenergic agonists during hypothermia